Table 2.
Prognostic Accuracy of Noninvasive Tests
| Noninvasive test (with abbreviation) | Chronic liver disease or setting | AUC (95% CI) |
|---|---|---|
| Assessment of hepatic fibrosis | ||
| AST to Platelet Ratio Index (APRI) | HCV | Significant fibrosis: 0.83 (0.78-0.88) Cirrhosis: 0.90 (0.86-0.94)13 |
| MASLD | 0.65 (0.53-0.73) to 0.72 (0.65-0.80)16 | |
| Fibrosis-4 (FIB-4) index | HCV | Significant fibrosis: 0.85 (0.82-0.89) Cirrhosis: 0.91 (0.86-0.93)17 |
| MASLD | 0.802 (0.76-0.85)19 | |
| NAFLD Fibrosis Score (NFS) | MASLD | Significant fibrosis: 0.8419 |
| FibroTest | HCV, HBV, alcohol, MASLD | Significant fibrosis (initial validation in HCV infection): 0.84 (0.78-0.88)15 |
| Enhanced Liver Fibrosis (ELF) test | MASLD | 0.90 (0.84-0.96)27 |
| FibroScan | HCV | Significant fibrosis (≥F2): 0.88 Cirrhosis: 0.9946 |
| MASLD | Significant fibrosis: 0.83 (0.79-0.87) Cirrhosis: 0.93 (0.90-0.97)47 | |
| FibroScan-AST (FAST) score | MASLD | 0.85 (0.83-0.87)50 |
| Acoustic radiation force impulse (ARFI) | MASLD | 0.87 (0.79-0.92)55 |
| Magnetic resonance elastography (MRE) | MASLD | Significant fibrosis: 0.93 (0.89-0.96) Cirrhosis: 0.94 (0.89-0.99)59 |
| LiverMultiScan | High-risk MASH | NAS ≥4, ≥F2: 0.78 (0.74-0.82)67 |
| Assessment of hepatic steatosis | ||
| Controlled attenuation parameter (CAP) | >10% of hepatic steatosis >33% of hepatic steatosis >66% of hepatic steatosis |
0.79 (0.74-0.84) 0.84 (0.80-0.88) 0.84 (0.80-0.88)43 |
| Magnetic resonance imaging proton density fat fraction (MRI-PDFF) | Steatosis grade 2 Steatosis grade 3 |
0.90 (0.82-0.97) 0.92 (0.84-0.99)63 |
| LiverMultiScan | Steatosis | 0.69 (0.64-0.74)67 |
AST, aspartate aminotransferase; AUC, area under the curve; HBV, hepatitis B virus; HCV, hepatitis C virus; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD Activity Score.